ATRC News and Press, AtriCure Inc. From 12/18/20

AtriCure has expertise in atrial fibrillation and key upcoming infection points that must be considered by investors. We believe the market is unfairly discounting the company's shares based on FDA overhang, however Convergent asset potential alongside the product mix outweigh this. ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39 th Annual J.P. Morgan Healthcare Conference being ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32 nd Annual Virtual Healthcare Conference. ...

AtriCure, Inc. (ATRC) Q3 2020 Results Conference Call November 05, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and CEO Angie Wirick - CFO Conference Call Participants Robby Marcus - JP Morgan Rick Wise - Stifel Danielle Antalffy - SVB Leerink Mat...

Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q3 2020 Earnings Call Transcript

AtriCure (ATRC): Q3 GAAP EPS of -$0.11 beats by $0.23.Revenue of $54.76M (-3.3% Y/Y) beats by $5.39M.Shares +1.7% AH.Press Release For further details see: AtriCure EPS beats by $0.23, beats on revenue

Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year AtriCure, Inc. ( Nasdaq: ATR...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a con...

Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction consider...

Among other criticisms, Kerrisdale Capital cites valuation as part of its short thesis on Atricure (ATRC), given it's near the "highest valuation in its history."Investors' assumptions on a "widespread adoption" of the Convergent procedure and growth in surgical devices are "misplaced."Shares...